16 stories mentioning HKG:2696Updated 6d ago
Every FINWIRES story that references HKG:2696, newest first.
Shanghai Henlius Biotech's (HKG:2696) new drug application for a new indication of Hansizhuang was approved by China's National Medical Products Administration, according to a Tuesday Hong Kong bourse filing.The approval is for use of the drug in combination with Oxaliplatin and S-1 for the neoadjuvanttreatment of resectable gastric cancer.
Shanghai Henlius Biotech (HKG:2696) dosed the first patient in an international multi-center phase 1 study of a HLX17 in the United States, according to a Friday Hong Kong bourse filing.The trial is studying the drug in patients with multiple resected solid tumors.A phase 1 trial of the drug is simultaneously being conducted in Mainland China.
Shanghai Henlius Biotech (HKG:2696) dosed the first patient in a phase 2/3 clinical study of HLX43 for injection, according to a Thursday Hong Kong bourse filing.The drug is being tested as monotherapy or in combination with pimurutamab HLX07 versus docetaxel for the treatment of advanced/metastatic squamous non-small cell lung cancer in patients whose prior treatment failed in the Chinese Mainland.
Shanghai Henlius Biotech (HKG:2696) dosed the first patient in a phase 2/3 trial studying pimurutamab HLX07 in combination with Hansizhuang and chemotherapy in the Chinese Mainland, according to a Tuesday filing with the Hong Kong bourse.The drug in this combination is being compared to placebo in combination with Hansizhuang or pembrolizumab and chemotherapy for the first-line treatment of advanced squamous non-small cell lung cancer.
Shanghai Henlius Biotech (HKG:2696) dosed the first patient in a phase 2/3 trial studying pimurutamab HLX07 in combination with Hansizhuang and chemotherapy in the Chinese Mainland, according to a Tuesday filing with the Hong Kong bourse.The drug in this combination is being compared to a placebo in combination with Hansizhuang or pembrolizumab and chemotherapy for the first-line treatment of advanced squamous non-small cell lung cancer.
Shanghai Henlius Biotech (HKG:2696) dosed the first patient in a phase 1 trial of HLX15-SC in the Chinese Mainland, according to a Tuesday Hong Kong bourse filing.The drug is being tested for first-line treatment for newly diagnosed multiple myeloma, the filing said.
Shanghai Henlius Biotech (HKG:2696) dosed the first patient in a Phase 1 clinical trial of HLX316 for injection, according to a Friday Hong Kong bourse filing.The trial is studying the effects of the drug in patients with advanced/metastatic solid tumors in Mainland China.
Shanghai Henlius Biotech (HKG:2696) obtained clinical trial approval for HLX48 for injection from China's National Medical Products Administration, according to a Thursday filing with the Hong Kong bourse.The firm developed the drug to treat advanced/metastatic solid tumors.
Shanghai Henlius Biotech (HKG:2696) obtained approval for a phase 1 clinical trial of the HLX3902 injection from Australia's Therapeutic Goods Administration, according to a Thursday filing with the Hong Kong bourse.The drug has been developed by the firm to treat metastatic castration-resistant prostate cancer and other advanced solid tumors.
Shanghai Henlius Biotech (HKG:2696) dosed the first patient in a phase 2 clinical study of HLX43 for injection in Spain, according to a Thursday filing with the Hong Kong bourse.The study aims to evaluate the drug in patients with advanced non-small cell lung cancer.The phase 2 trial is also ongoing in Mainland China, the U.S., Australia, and Japan.
Shanghai Henlius Biotech (HKG:2696) obtained approval for a phase 1 clinical trial of HLX48 for injection from Australia's relevant regulatory authorities, according to a Wednesday Hong Kong bourse filing.The drug will be tested for the treatment of advanced/metastatic solid tumors.
Shanghai Henlius Biotech (HKG:2696) dosed the first patient in a phase 1 clinical study of HLX97, according to a Wednesday Hong Kong bourse filing.The trial is testing patients with advanced/metastatic solid tumours in Mainland China.
Shanghai Henlius Biotech (HKG:2696) secured an implied approval for the phase 2/3 clinical trial of HLX43 for injection in Japan by the country's Pharmaceuticals and Medical Devices Agency, according to a Monday Hong Kong bourse filing.The drug is being tested as monotherapy or in combination with pimurutamab HLX07 versus Docetaxel for advanced squamous non-small cell lung cancer.The firm will begin the trial once the relevant conditions are fulfilled, the filing said.
Shanghai Henlius Biotech (HKG:2696) dosed the first patient in a phase 1 clinical study of HLX3901 in mainland China, according to a Thursday Hong Kong bourse filing.The drug is being tested for the treatment of patients with advanced small-cell lung cancer or neuroendocrine carcinoma.
Shanghai Henlius Biotech (HKG:2696) obtained approval from Australian regulatory authorities for a phase 2/3 clinical trial of pimurutamab HLX07, according to a Friday Hong Kong bourse filing.The drug is being studied in combination with Hansizhuang for the treatment of advanced squamous non-small cell lung cancer.
Shanghai Henlius Biotech (HKG:2696) obtained approval for a phase 1 clinical trial of HLX05-N from China's National Medical Products Administration, according to a Tuesday Hong Kong bourse filing.The drug is being studied for the treatment of metastatic colorectal cancer.
